Novocure’s stock rises 37% on FDA clearance of pancreatic cancer treatment device
The US Food & Drug Administration (FDA) has cleared Novocure’s Optune Pax device for locally advanced pancreatic cancer treatment, representing the first clearance by the agency in this indication since Eli Lilly’s Gemzar (gemcitabine) chemotherapy …